Stay current with MiRXES
Newsroom > Media Releases
MiRXES appoints David Capes as its new Global Head of Innovation
SINGAPORE, 20 September 2021 – MiRXES Pte Ltd, a biotechnology company focused on improving and saving lives with RNA-powered disease early detection tests, announced today the appointment of Dr. David CAPES as Senior Vice President and Global Head of Innovation. In this newly created role, Dr. Capes will focus on the transformation of MIRXES from a regional SME to a global innovation enterprise over the next three years, through the development and implementation of a global innovation strategy, the prioritization of MiRXES’s clinical pipeline, and the refinement of the global regulatory and market entry strategy. Based in Singapore, Dr. Capes will report to MiRXES’s Co-founder and CEO, Dr. Lihan ZHOU.
“Innovation has been one of the key driving forces of MiRXES. We are delighted to have David’s expertise in this domain to create a system for innovation where new ideas can be realized and commercialized,” said Dr. Zhou. “I am confident that with David’s distinguished experience in inspiring and mentoring diverse talent, he can strengthen MiRXES’s culture of innovation where our leaders and people can expand their skills on technology innovation, partner engagement and people management, as we continue our global expansion in disease early detection and precision medicine.”
Dr. Capes brings with him over 31 years of extensive biomedical technology industry experience across all facets of general management and strategy, research and development, innovation, organic and inorganic opportunity identification and development, quality management, regulatory affairs management, manufacturing and sales. He was most recently the Vice President of R&D for Greater Asia at Becton-Dickinson (BD), where he led the strategic innovation team and was instrumental in establishing the idea portfolio management for their new product development (NPD) portfolio. Dr. Capes was phenomenal in leading overachievement of the revenue target of innovation to NPD project approvals by five-fold.
“I am thrilled to join a company like MiRXES which has an innovative and collaborative culture. I look forward to shaping and bolstering MiRXES’s global innovation strategy and working together with the highly talented teams to accomplish breakthroughs in our disease early detection solutions and precision medicine. Successful innovation is critical to fulfil MiRXES’s purpose of saving and improving lives on a global stage,” said Dr. Capes.
Dr. Capes has an excellent track record in building and growing teams in multinationals and start-ups in Singapore, China, Australia and India. Prior to BD, Dr. Capes held senior management roles in Pathway Biomed and Rockeby Biomed.
Dr. Capes holds a PhD in Pharmacy from Curtin University and has two U.S. patents granted.